Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome.

Author: Chul Won JUNG ¹
Author Information

1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. leukemia1@skku.edu
Publication Type:Letter
MeSH: Primary Myelofibrosis; Pyrazoles; Transplants
From:Blood Research 2013;48(1):68-69
CountryRepublic of Korea
Language:English
Abstract: No abstract available.